Monday, 23 July 2018 - 3:00
  • it
  • de
  • en
  • fr

Crohn’s disease

Tigenix obtains ODD by FDA for Chron’s disease therapy (Cx601)

Leuven, Belgium-based TiGenix today obtained by the FDA an ODD (Orphan Drug Designation) for its Cx601 investigational therapy, developed to treat fistulas in patients with Crohn’s disease. Cx601 is an allogeneic, stem-cells therapy already assessed in two Phase III clinical…

Takeda targets Tigenix

Belgium-based Tigenix reportedly attracted interest from Japan-based group Takeda, Tigenix CEO Eduardo Bravo reported to Belgian daily De Tijd, adding that talks started as early as last year, when Takeda invested €25m in Tigenix. Tigenix focuses on developing anti-inflammatory therapies…

AstraZeneca, agreement with Allergan for inflammatory diseases

AstraZeneca today announced that MedImmune, its R&D arm, has signed a licensing agreement with Allergan for the global rights to MEDI2070, an IL-23 monoclonal antibody currently in a Phase IIb clinical trial. The ongoing trial has been designed to evaluate…